News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Novartis AG’s Drug Onbrez Breezhaler Proved More Effective Against COPD than Other Drugs
September 20, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Reuters) - Novartis' lung drug Onbrez Breezhaler allows patients with a deadly lung disease to breathe more easily than a current mainstay treatment, adding to positive sentiment surrounding the Swiss drugmaker.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
Novartis
MORE ON THIS TOPIC
Drug Development
Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’
November 4, 2026
·
3 min read
·
Heather McKenzie
Podcast
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
November 4, 2026
·
1 min read
·
Jef Akst
Psychedelics
Compass to submit psilocybin depression drug for approval imminently after stock wobbles
November 3, 2026
·
2 min read
·
Heather McKenzie
Deals
Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance
November 3, 2026
·
1 min read
·
Gabrielle Masson